CA2444691A1 - Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer - Google Patents

Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer Download PDF

Info

Publication number
CA2444691A1
CA2444691A1 CA002444691A CA2444691A CA2444691A1 CA 2444691 A1 CA2444691 A1 CA 2444691A1 CA 002444691 A CA002444691 A CA 002444691A CA 2444691 A CA2444691 A CA 2444691A CA 2444691 A1 CA2444691 A1 CA 2444691A1
Authority
CA
Canada
Prior art keywords
lung cancer
sequence
protein
antibody
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002444691A
Other languages
English (en)
French (fr)
Inventor
Natasha Aziz
Richard Murray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PDL Biopharma Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2444691A1 publication Critical patent/CA2444691A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57449Specifically defined cancers of ovaries
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002444691A 2001-04-18 2002-04-18 Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer Abandoned CA2444691A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US28477001P 2001-04-18 2001-04-18
US60/284,770 2001-04-18
US29049201P 2001-05-10 2001-05-10
US60/290,492 2001-05-10
US33924501P 2001-11-09 2001-11-09
US60/339,245 2001-11-09
US35066601P 2001-11-13 2001-11-13
US60/350,666 2001-11-13
US33437001P 2001-11-29 2001-11-29
US60/334,370 2001-11-29
US37224602P 2002-04-12 2002-04-12
US60/372,246 2002-04-12
PCT/US2002/012476 WO2002086443A2 (en) 2001-04-18 2002-04-18 Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer

Publications (1)

Publication Number Publication Date
CA2444691A1 true CA2444691A1 (en) 2002-10-31

Family

ID=27559574

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002444691A Abandoned CA2444691A1 (en) 2001-04-18 2002-04-18 Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer

Country Status (5)

Country Link
EP (1) EP1463928A2 (de)
JP (1) JP2005527180A (de)
AU (1) AU2002309583A1 (de)
CA (1) CA2444691A1 (de)
WO (1) WO2002086443A2 (de)

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168980A1 (de) * 2000-06-23 2010-03-31 Genentech, Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
US7265210B2 (en) 2000-09-15 2007-09-04 Genentech, Inc. Anti-PRO9821 antibodies
AU2002226079A1 (en) 2000-12-08 2002-06-18 Curagen Corporation Method of detecting and treating tuberous sclerosis complex associated disorders
US20060035237A1 (en) * 2002-08-26 2006-02-16 Markowitz Sanford D Methods and compositions for categorizing patients
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
EP1402053A4 (de) * 2001-06-05 2005-05-11 Exelixis Inc Chds als modifikatoren des p53-wegs und verwendungsverfahren
AU2002343443A1 (en) * 2001-09-28 2003-04-14 Whitehead Institute For Biomedical Research Classification of lung carcinomas using gene expression analysis
WO2003054512A2 (en) * 2001-12-20 2003-07-03 Tularik Inc. Identification of an amplified gene and target for drug intervention
EP1361433A3 (de) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Verfahren zur erkennung die therapeutisches Wirkung TNF
DE10225144A1 (de) * 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
EP1552845A4 (de) * 2002-06-26 2006-06-07 Takeda Pharmaceutical Mittel zur prävention/behandlung von krebs
GB0215224D0 (en) * 2002-07-01 2002-08-14 Inpharmatica Ltd Protein
US7803370B2 (en) 2002-08-30 2010-09-28 Oncotherapy Science, Inc. Method for treating synovial sarcoma
AU2003256079A1 (en) * 2002-08-30 2004-03-19 Japan As Represented By President Of The University Of Tokyo Method for treating synovial sarcoma
DE60335636D1 (de) * 2002-09-11 2011-02-17 Genentech Inc Zusammensetzungen und verfahren für die tumordiagnose und behandlung
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
AU2003301160A1 (en) * 2002-12-20 2004-07-22 Avalon Pharmaceuticals Amplified cancer target genes useful in diagnosis and therapeutic screening
AU2003292737A1 (en) * 2002-12-24 2004-07-22 Takeda Pharmaceutical Company Limited Preventives/remedies for cancer
EP1577322A4 (de) * 2002-12-26 2006-01-25 Takeda Pharmaceutical Neue proteine und ihre verwendung
EP1599606A1 (de) * 2003-03-03 2005-11-30 Arizona Board of Regents on behalf of The University of Arizona Benutzung von protein thyrosine phosphatase (prl-1) als marker und therapeutisches zielmolekul für pankreaskrebs
CA2518662C (en) * 2003-03-11 2014-06-17 The University Of British Columbia Diagnosis of gynecological neoplasms by detecting the levels of oviduct-specific glycoprotein
EP1606303A4 (de) * 2003-03-24 2007-11-21 Corixa Corp Nachweis und die beobachtung von lungenkrebs
AU2003901511A0 (en) * 2003-03-28 2003-04-17 Bionomics Limited Nucleic acid molecules associated with angiogenesis II
ATE494550T1 (de) 2003-04-25 2011-01-15 Takeda Pharmaceutical Neues screening-verfahren
WO2004097034A2 (en) * 2003-05-02 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 4 (tmprss4)
WO2005000098A2 (en) * 2003-06-10 2005-01-06 The Trustees Of Boston University Detection methods for disorders of the lung
WO2004111197A2 (en) * 2003-06-10 2004-12-23 Trustees Of Boston University Gene expression signatures, methods and compositions for diagnosing disorders of the lung
WO2005002417A2 (en) * 2003-06-20 2005-01-13 Avalon Pharmaceuticals, Inc. Cancer -linked gene aas target for chemotherapy
CA2532722C (en) * 2003-07-17 2016-10-04 Pacific Edge Biotechnology, Ltd. Cystatin sn (cst1) and other markers for detection of gastric cancer
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
WO2005059109A2 (en) * 2003-12-15 2005-06-30 The Regents Of The University Of California Molecular signature of the pten tumor suppressor
WO2006131783A2 (en) * 2004-01-27 2006-12-14 Compugen Usa, Inc. Polynucleotides, polypeptides, and diagnosing lung cancer
JP2005230011A (ja) 2004-02-20 2005-09-02 Samsung Electronics Co Ltd 乳ガン関連蛋白質、それをコーディングする遺伝子、及び該蛋白質及び該遺伝子を利用した乳ガンの診断方法
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US7399469B2 (en) * 2004-03-26 2008-07-15 Pdl Biopharma, Inc. Anti-LFL2 antibodies for the diagnosis, prognosis and treatment of cancer
JP2005314397A (ja) * 2004-03-31 2005-11-10 Mitsubishi Chemicals Corp 抗コンドロモジュリン−1特異的抗体及びその利用
US7781175B2 (en) 2004-04-23 2010-08-24 Takeda Pharmaceutical Company Limited Method of screening compounds which alter the binding properties of GPR39, and homologs thereof, to bile acid
DE102004023187A1 (de) * 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
EP1760087B1 (de) 2004-06-03 2010-04-21 Takeda Pharmaceutical Company Limited Neuer proteinkomplex und anwendungen davon
US20110177079A1 (en) * 2004-09-08 2011-07-21 Ludwig Institute For Cancer Research Cancer-testis antigens
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
US8034578B2 (en) * 2004-10-19 2011-10-11 Oncotherapy Science, Inc. PKP3 oncogene as a prognostic indicator for lung cancer
WO2006084694A2 (en) * 2005-02-10 2006-08-17 Centre National De La Recherche Scientifique Use of the mcm8 gene for the preparation of a pharmaceutical composition
DK2325305T3 (en) 2005-02-25 2014-03-03 Oncotherapy Science Inc Peptide vaccines for cancers that express TTK-, URLC10- or KOC1 polypeptide
DE102005013846A1 (de) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
US20100035244A1 (en) 2005-04-14 2010-02-11 The Trustees Of Boston University Diagnostic for lung disorders using class prediction
GB0508863D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Peptide
US8147838B2 (en) * 2005-05-13 2012-04-03 Oxford Biomedica (Uk) Limited Peptide
KR101373464B1 (ko) 2005-12-08 2014-03-14 메다렉스, 엘.엘.시. 단백질 티로신 키나제 7(ptk7)에 대한 인간 단일클론항체 및 그의 용도
GB0526498D0 (en) * 2005-12-28 2006-02-08 Randox Lab Ltd Method
WO2007103541A2 (en) 2006-03-09 2007-09-13 The Trustees Of Boston University Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
BRPI0709338A2 (pt) 2006-03-21 2011-07-12 Genentech Inc anticorpo, molécula de ácido nucleico isolada, célula, composições, método de detecção da proteìna alfa5beta1, uso de anticorpo, métodos de tratamento, kit, uso de uma composição, uso de uma antagonista de alfa5beta e uso de uma antagonista de vegf
JP5298266B2 (ja) * 2006-03-31 2013-09-25 静岡県 小細胞肺癌の判定用キット
JP5114637B2 (ja) * 2006-03-31 2013-01-09 静岡県 小細胞肺癌の判定方法
WO2007148417A1 (en) 2006-06-21 2007-12-27 Oncotherapy Science, Inc. Tumor-targeting monoclonal antibodies to fzd10 and uses thereof
EP3231442B1 (de) * 2006-06-23 2019-12-25 ADC Therapeutics SA An krebs beteiligte polynukleotide und polypeptidsequenzen
US20100092457A1 (en) 2006-08-14 2010-04-15 Forerunner Pharma Research Co., Ltd. Diagnosis and Treatment of Cancer Using Anti-Desmoglein-3 Antibodies
EP1932854A1 (de) * 2006-12-15 2008-06-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Lysosomal assoziiertes Membranprotein (LAMP) wie Polypeptide, Liganden dazu und Verwendung davon im Rahmen der Detektion und Reinigung menschlicher, plasmazytoider dendritischer Zellen
TWI610939B (zh) * 2007-02-21 2018-01-11 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
JP2010528261A (ja) 2007-05-08 2010-08-19 ピコベラ・リミテッド・ライアビリティ・カンパニー 前立腺癌および肺癌の診断および治療方法
CA2688299A1 (en) * 2007-05-29 2008-12-18 President And Fellows Of Harvard College Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof
SI2185198T1 (sl) 2007-08-02 2015-04-30 Gilead Biologics, Inc. Inhibitorji LOX in LOXL2 ter njihova uporaba
EP2192179B9 (de) 2007-08-20 2017-11-15 Oncotherapy Science, Inc. Cdh3-peptid und dieses enthaltendes arzneimittel
CN101835893A (zh) * 2007-08-24 2010-09-15 肿瘤疗法科学股份有限公司 癌症相关基因cdca5、epha7、stk31和wdhd1
WO2009032292A1 (en) * 2007-09-06 2009-03-12 Case Western Reserve University Methods for diagnosing and treating cancers
JP2010538680A (ja) 2007-09-19 2010-12-16 ザ トラスティーズ オブ ボストン ユニバーシティー 肺疾患に対する薬剤開発のための新規経路の同定
SI2200700T1 (sl) 2007-09-26 2016-04-29 Genentech, Inc. Nova protitelesa
WO2010009124A2 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
CA3011730C (en) * 2008-09-09 2022-05-17 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
EP2342334A4 (de) * 2008-09-29 2012-03-14 Univ Pennsylvania Auf tumorgefässmarker gerichtete impfstoffe
RU2532105C2 (ru) 2008-10-22 2014-10-27 Онкотерапи Сайенс, Инк. Эпитопные пептиды rab6kifl/kif20a и содержащие их вакцины
WO2010047028A1 (en) * 2008-10-24 2010-04-29 Oncotherapy Science, Inc. Screening method of anti-lung or esophageal cancer compounds
CN102245773B (zh) 2008-11-03 2014-08-27 阿莱斯亚生物疗法股份有限公司 特异性地阻滞肿瘤抗原的生物活性的抗体
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
WO2010080769A2 (en) 2009-01-06 2010-07-15 Arresto Biosciences, Inc. Chemotherapeutic methods and compositions
US9155805B2 (en) * 2009-02-20 2015-10-13 Perseus Proteomics Inc. Monoclonal antibody, and use thereof
MX2011010012A (es) 2009-03-25 2011-12-06 Genentech Inc NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS.
WO2010129934A2 (en) 2009-05-07 2010-11-11 Veracyte, Inc. Methods and compositions for diagnosis of thyroid conditions
TW201102081A (en) 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
SG2014004816A (en) 2009-08-21 2014-03-28 Gilead Biologics Inc Catalytic domains from lysyl oxidase and loxl2
IN2012DN03025A (de) 2009-09-09 2015-07-31 Ct Se Llc
EP2494362B1 (de) 2009-10-26 2016-06-08 Externautics S.p.A. Prostatakrebs markers und methoden deren verwendung
US20120322075A1 (en) * 2009-10-26 2012-12-20 Externautics S.P.A. Lung Tumor Markers and Methods of Use Thereof
WO2011051280A1 (en) 2009-10-26 2011-05-05 Externautics S.P.A. Ovary tumor markers and methods of use thereof
US9745589B2 (en) 2010-01-14 2017-08-29 Cornell University Methods for modulating skeletal remodeling and patterning by modulating SHN2 activity, SHN3 activity, or SHN2 and SHN3 activity in combination
PE20130342A1 (es) 2010-04-15 2013-04-20 Spirogen Sarl Pirrolobenzodiacepinas y conjugados de las mismas
RU2626537C2 (ru) 2010-06-08 2017-07-28 Дженентек, Инк. Полученные с помощью генной инженерии антитела с цистеиновыми заменами и их конъюгаты
MX355020B (es) * 2010-07-09 2018-04-02 Somalogic Inc Biomarcadores de cancer de pulmon y usos de los mismos.
BR112013003391B8 (pt) 2010-08-13 2022-10-25 Somalogic Inc Método para diagnosticar câncer pancreático em um indivíduo
MX337873B (es) 2010-09-29 2016-03-23 Agensys Inc Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12.
ES2544608T3 (es) 2010-11-17 2015-09-02 Genentech, Inc. Conjugados de anticuerpo y de alaninil-maitansinol
BR112013025198A2 (pt) 2011-03-31 2018-12-04 Alethia Biotherapeutics Inc. anticorpos contra antígeno 1 associado a rim e fragmentos de ligação a antígeno do mesmo
WO2012155019A1 (en) 2011-05-12 2012-11-15 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
EP2750713B1 (de) 2011-10-14 2015-09-16 Spirogen Sàrl Pyrrolobenzodiazepine und konjugate daraus
KR102102239B1 (ko) 2012-01-09 2020-04-21 에이디씨 테라퓨틱스 에스에이 유방암을 치료하기 위한 방법
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
EP2906250B1 (de) 2012-10-12 2018-05-30 ADC Therapeutics SA Pyrrolobenzodiazepin-anti-psma-antikörperkonjugate
PL2906253T3 (pl) 2012-10-12 2019-02-28 Adc Therapeutics Sa Koniugaty pirolobenzodiazepina-przeciwciało anty-psma
ES2660029T3 (es) 2012-10-12 2018-03-20 Medimmune Limited Conjugados de anticuerpo-pirrolobenzodiazepinas
KR101819404B1 (ko) 2012-10-12 2018-02-28 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨주게이트
AU2013328628B2 (en) 2012-10-12 2016-12-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
CN105102068B (zh) 2012-10-12 2018-06-01 Adc疗法责任有限公司 吡咯并苯并二氮杂卓-抗体结合物
MX364329B (es) 2012-10-12 2019-04-23 Medimmune Ltd Conjugados del anticuerpo pirrolobenzodiazepina.
CA2894959C (en) 2012-12-21 2022-01-11 Spirogen Sarl Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
CN110452242A (zh) 2012-12-21 2019-11-15 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
BR112015023070B1 (pt) 2013-03-13 2022-06-07 Genentech, Inc. Conjugados e compostos de pirrolobenzodiazepinas, composição farmacêutica que compreende os mesmo, bem como seus usos para o tratamento de uma doença proliferativa
KR102066318B1 (ko) 2013-03-13 2020-01-14 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドMedImmune Limited ピロロベンゾジアゼピン及びその結合体
EP3626308A1 (de) 2013-03-14 2020-03-25 Veracyte, Inc. Verfahren zur bewertung eines copd-status
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
BR112016002829A2 (pt) 2013-08-12 2017-09-19 Genentech Inc Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
MX371092B (es) 2013-12-16 2020-01-16 Genentech Inc Compuestos peptidomimeticos y conjugados de anticuerpo-farmaco de los mismos.
KR20160092024A (ko) 2013-12-16 2016-08-03 제넨테크, 인크. 1-(클로로메틸)-2,3-디히드로-1H-벤조[e]인돌 이량체 항체-약물 접합체 화합물, 및 사용 및 치료 방법
EA201691023A1 (ru) 2013-12-16 2016-10-31 Дженентек, Инк. Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
KR20170052600A (ko) 2014-09-12 2017-05-12 제넨테크, 인크. 시스테인 가공된 항체 및 콘주게이트
US10149913B2 (en) 2014-09-12 2018-12-11 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
AU2015317653A1 (en) 2014-09-17 2017-04-06 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
EP3770274A1 (de) 2014-11-05 2021-01-27 Veracyte, Inc. Systeme und verfahren zur diagnose von idiopathischer pulmonaler fibrose auf transbronchialen biopsien mit maschinellem lernen und hochdimensionalen transkriptionsdaten
CN107148285B (zh) 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
CN107206101B (zh) 2014-12-03 2021-06-25 基因泰克公司 季铵化合物及其抗体-药物缀合物
DK3388075T5 (da) 2015-03-27 2024-09-23 Immatics Biotechnologies Gmbh Hidtil ukendte peptider og kombination af peptider til anvendelse ved immunterapi mod forskellige tumorer
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201603568D0 (en) * 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
JP6943872B2 (ja) 2016-03-25 2021-10-06 ジェネンテック, インコーポレイテッド 多重全抗体及び抗体複合体化薬物定量化アッセイ
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
US10927417B2 (en) 2016-07-08 2021-02-23 Trustees Of Boston University Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
CN110139674B (zh) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 制备抗体药物缀合物的方法
TWI762516B (zh) 2016-10-06 2022-05-01 日商腫瘤療法 科學股份有限公司 針對fzd10之單株抗體及其用途
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
PL3544636T3 (pl) 2017-02-08 2021-12-06 Adc Therapeutics Sa Koniugaty pirolobenzodiazepina-przeciwciało
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
RS63502B1 (sr) 2017-04-18 2022-09-30 Medimmune Ltd Konjugati pirolobenzodiazepina
CA3057748A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
US11318211B2 (en) 2017-06-14 2022-05-03 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
NZ761175A (en) 2017-08-18 2024-07-26 Medimmune Ltd Pyrrolobenzodiazepine conjugates
TW201920192A (zh) 2017-09-20 2019-06-01 韓商Ph製藥公司 泰蘭他汀(thailanstatin)類似物
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
WO2020086858A1 (en) 2018-10-24 2020-04-30 Genentech, Inc. Conjugated chemical inducers of degradation and methods of use
WO2020123275A1 (en) 2018-12-10 2020-06-18 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
CN113321720B (zh) * 2021-03-24 2022-03-01 深圳市新靶向生物科技有限公司 一种与肝癌驱动基因突变相关的抗原肽组合及其应用
WO2023217735A1 (en) * 2022-05-13 2023-11-16 Hummingbird Diagnostics Gmbh Novel rna molecule for cancer detection
WO2024138128A2 (en) 2022-12-23 2024-06-27 Genentech, Inc. Cereblon degrader conjugates, and uses thereof

Also Published As

Publication number Publication date
WO2002086443A8 (en) 2004-06-17
WO2002086443A2 (en) 2002-10-31
AU2002309583A1 (en) 2002-11-05
EP1463928A2 (de) 2004-10-06
JP2005527180A (ja) 2005-09-15

Similar Documents

Publication Publication Date Title
CA2444691A1 (en) Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
US7736853B2 (en) Methods of diagnosis of androgen-dependent prostate cancer, prostate cancer undergoing androgen withdrawal, and androgen-independent prostate cancer
US7435589B2 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20030124579A1 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
WO2004063355A2 (en) Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
CA2453098A1 (en) Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
CA2425569A1 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
US20040253606A1 (en) Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
CA2451465A1 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20030235820A1 (en) Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
US20100297152A1 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
CA2459219A1 (en) Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
US20030232350A1 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20070054268A1 (en) Methods of diagnosis and prognosis of ovarian cancer
US20070059748A1 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
CA2440703A1 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
CA2438030A1 (en) Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
US20030228570A1 (en) Methods of diagnosis of Hepatitis C infection, compositions and methods of screening for modulators of Hepatitis C infection
WO2004073657A2 (en) Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases
CA2381699A1 (en) Novel methods of diagnosis of angiogenesis compostions and methods of screening for angiogenesis modulators
US20040146862A1 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
US6455668B1 (en) Methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
US20080138838A1 (en) Diagnosis of zd1839 resistant tumors
CA2467433A1 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
EP1847620A2 (de) Verfahren zur Diagnose von Prostatakrebs, Zusammensetzungen und Verfahren zum Screening für Modulatoren von Prostatakrebs

Legal Events

Date Code Title Description
FZDE Dead